((自动化翻译由路透提供，请见免责声明 ))
10月24日 - ** 药物开发商Viking Therapeutics 股价上涨19.32%至72.06美元
** 该公司将在即将召开的会议上展示其口服肥胖症药物VK2735的60/80/100毫克剂量的数据
** Stifel分析师Annabel Samimy说，鉴于之前的剂量观察到的良好反应，该券商对看到与其他治疗方法相比具有竞争力的减肥效果持乐观态度。
** Samimy 补充说，这种药物是耐受性最好的药物之一，加上良好的疗效，显示出 "同类最佳 "的潜力
** VKTX 周三晚些时候表示， (link)，预计口服 VK2735 可通过延长服药期进一步获益。
** 补充说，已对每日剂量高达 100 毫克的剂量递增进行了评估
** 公司将在下月举行的肥胖周上展示数据，并计划在今年晚些时候启动一项中期研究
** 券商奥本海默（Oppenheimer）表示，VKTX 在中期研究中的剂量可能超过 100 毫克
** 今年以来股价已上涨近两倍
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.